ChitogenX Inc. (CHNXF)
USD 0.01
(-13.38%)
USD 0.01
(-13.38%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 6.71 Million CAD | -36.57% |
| 2023 | 10.58 Million CAD | 28.61% |
| 2022 | 8.22 Million CAD | 48.31% |
| 2021 | 5.54 Million CAD | 36.26% |
| 2020 | 4.07 Million CAD | 85.65% |
| 2019 | 2.19 Million CAD | 60.63% |
| 2018 | 1.36 Million CAD | -32.2% |
| 2017 | 2.01 Million CAD | 40.66% |
| 2016 | 1.43 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 6.61 Million CAD | -38.96% |
| 2024 Q3 | 6.71 Million CAD | 1.57% |
| 2024 Q4 | 6.71 Million CAD | -0.03% |
| 2024 FY | 6.71 Million CAD | -36.57% |
| 2024 Q1 | 10.82 Million CAD | 2.34% |
| 2023 Q1 | 7.84 Million CAD | -4.68% |
| 2023 Q3 | 8.66 Million CAD | 12.64% |
| 2023 Q4 | 10.58 Million CAD | 22.18% |
| 2023 FY | 10.58 Million CAD | 28.61% |
| 2023 Q2 | 7.68 Million CAD | -1.96% |
| 2022 Q2 | 6.05 Million CAD | 15.16% |
| 2022 Q4 | 8.22 Million CAD | 13.19% |
| 2022 FY | 8.22 Million CAD | 48.31% |
| 2022 Q1 | 5.25 Million CAD | 3.53% |
| 2022 Q3 | 7.26 Million CAD | 20.05% |
| 2021 Q1 | 4.11 Million CAD | 11.64% |
| 2021 FY | 5.54 Million CAD | 36.26% |
| 2021 Q3 | 3.99 Million CAD | -12.81% |
| 2021 Q4 | 5.07 Million CAD | 27.08% |
| 2021 Q2 | 4.58 Million CAD | 11.37% |
| 2020 Q4 | 3.68 Million CAD | 7.9% |
| 2020 FY | 4.07 Million CAD | 85.65% |
| 2020 Q3 | 3.41 Million CAD | 20.54% |
| 2020 Q1 | 2.17 Million CAD | -0.82% |
| 2020 Q2 | 2.83 Million CAD | 30.24% |
| 2019 Q1 | 1.35 Million CAD | -0.96% |
| 2019 Q2 | 862.14 Thousand CAD | -36.24% |
| 2019 Q3 | 1.26 Million CAD | 46.5% |
| 2019 Q4 | 2.19 Million CAD | 73.7% |
| 2019 FY | 2.19 Million CAD | 60.63% |
| 2018 Q3 | 1.39 Million CAD | -8.46% |
| 2018 FY | 1.36 Million CAD | -32.2% |
| 2018 Q2 | 1.52 Million CAD | -6.28% |
| 2018 Q1 | 1.62 Million CAD | -19.3% |
| 2018 Q4 | 1.36 Million CAD | -2.08% |
| 2017 Q1 | 1.18 Million CAD | -17.08% |
| 2017 Q2 | 1.72 Million CAD | 45.46% |
| 2017 Q4 | 2.01 Million CAD | 18.56% |
| 2017 Q3 | 1.69 Million CAD | -1.64% |
| 2017 FY | 2.01 Million CAD | 40.66% |
| 2016 FY | 1.43 Million CAD | 0.0% |
| 2016 Q4 | 1.43 Million CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -700.256% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -166.738% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -30.431% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 90.738% |
| GB Sciences, Inc. | 5.41 Million USD | -23.893% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -83.13% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -328.505% |
| Skye Bioscience, Inc. | 14.07 Million USD | 52.303% |
| Zenith Capital Corp. | 27.56 Thousand USD | -24246.186% |
| Agentix Corp. | 2.51 Million USD | -167.351% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 29.093% |
| Biomind Labs Inc. | 1.49 Million USD | -347.881% |
| ContraFect Corporation | 32.53 Million USD | 79.367% |
| CSL Limited | 18.62 Billion USD | 99.964% |
| CytoDyn Inc. | 127.89 Million USD | 94.752% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -368.107% |
| Neon Bloom, Inc. | 1.22 Million USD | -447.376% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 91.041% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -14917.004% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -74.273% |
| Regen BioPharma, Inc. | 5.45 Million USD | -22.984% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 88.626% |
| SQZ Biotechnologies Company | 50.03 Million USD | 86.586% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -233.909% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 87.408% |
| Intellipharmaceutics International Inc. | 12 Million USD | 44.108% |
| Mesoblast Limited | 188.44 Million USD | 96.438% |
| Marizyme, Inc. | 26.67 Million USD | 74.839% |
| Genus plc | 485 Million USD | 98.616% |
| Pharming Group N.V. | 244.07 Million USD | 97.25% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -76.632% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -75.356% |
| IMV Inc. | 37.93 Million USD | 82.306% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 43.013% |
| MultiCell Technologies, Inc. | 1617.67 USD | -414817.752% |
| ONE Bio Corp. | 27.49 Million USD | 75.589% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 91.33% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 91.907% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 25.77% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 63.529% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4623.6% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -3237.377% |
| Alpha Cognition Inc. | 7.16 Million USD | 6.319% |
| Enzolytics Inc. | 365.26 Million USD | 98.162% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.492% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -291.599% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 72.876% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.494% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 29.952% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1492.151% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -79.739% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -885.85% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -147.525% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -14.88% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -238.766% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | -521.92% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -9928.538% |
| EV Biologics, Inc. | 2.11 Million USD | -217.342% |
| Q BioMed Inc. | 8.13 Million USD | 17.471% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 86.647% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 94.346% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 57.799% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -16.815% |
| HST Global, Inc. | 593.59 Thousand USD | -1030.741% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -24366.883% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -433.04% |
| Halberd Corporation | 728.71 Thousand USD | -821.068% |
| Resverlogix Corp. | 67.39 Million USD | 90.041% |
| Cell Source, Inc. | 15.8 Million USD | 57.537% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 43.611% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | -68.063% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2712.44% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | 14.614% |
| Kadimastem Ltd | 3.5 Million USD | -91.505% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -227.165% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1344.376% |
| LadRx Corporation | 2.2 Million USD | -205.018% |
| Regen BioPharma, Inc. | 5.45 Million USD | -22.984% |
| Affymax, Inc. | 8.87 Million USD | 24.338% |
| Itoco Inc. | 1.65 Million USD | -306.013% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -10.96% |
| Mobile Lads Corp. | 1.31 Million USD | -411.002% |
| International Stem Cell Corporation | 5.27 Million USD | -27.193% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.24 Million USD | -106.555% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -15957.8% |
| Qrons Inc. | 1.48 Million USD | -350.859% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 39.232% |
| SYBLEU INC | 681.41 Thousand USD | -885.012% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -729.878% |
| Rebus Holdings, Inc. | 5.24 Million USD | -28.043% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -9.998% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -972.532% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -45.372% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 83.628% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 69.854% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -231.393% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -22.526% |
| Neutra Corp. | 973.52 Thousand USD | -589.45% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 76.867% |
| PureTech Health plc | 125.58 Million USD | 94.655% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -78.647% |
| IXICO plc | 1.9 Million USD | -253.209% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 67.305% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 93.504% |
| CSL Limited | 18.62 Billion USD | 99.964% |
| Cellectis S.A. | 249.36 Million USD | 97.308% |